NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, announced new data from the AUGMENT-101 trial of their menin inhibitor, Revuforj® (revumenib), during the 30th European Hematology Association Annual Congress. These findings have led to the FDA approval of Revuforj for patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. Additionally, these results underpin a supplemental New Drug Application (NDA) submitted to the FDA for treating relapsed or refractory mutant NPM1 acute myeloid leukemia $(AML.AU)$, addressing a significant unmet medical need.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。